Immuron develops and commercialises oral immunotherapeutic products targeting gut-mediated diseases, including its Travelan® travel-diarrhea product. The company is pursuing an organic growth and M&A strategy built on expanding market verticals, customer base, distribution and product offerings. Immuron has committed cash reserves to a strategic equity investment in Ateria Health to gain exposure to the IBS market and complementary products. Management intends to leverage reciprocal distribution, joint R&D and sales & marketing to expand Travelan® and incorporate Ateria’s JUVIA™ in new markets. The company funded the upfront investment from existing cash reserves and views the deal as the first milestone in its stated growth strategy.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2022